Skip to main content
. 2017 Dec 6;27(3):486–498. doi: 10.1093/hmg/ddx418

Figure 8.

Figure 8.

Subcutaneous delivery of ASO10–29 partially corrects the heart pathology of SMA mice. ASO in saline or saline alone was injected into mice at 90 mg/kg, twice between P0 and P1, and cardiac tissues were collected on P6 for various analyses. Heterozygous mice (Het) were used as controls. (A) Analysis of SMN2 exon 7 inclusion by radioactive RT–PCR after ASO treatment. FL, full-length transcript; Δ7, exon 7-skipped transcript; Incl %, 100 × FL/(FL + Δ7). (B) Western blotting analysis of SMN levels, normalized to β-tubulin. (C) Histogram of exon 7 inclusion data after ASO treatment as in (A) (n = 4). (D) Histogram of SMN levels from (B) (n = 3). (E) Heart weight after ASO treatment (n = 10). (F) Ratio of heart weight to body weight (mg/g, n = 10). (G) Quantitation of gene expression (Birc5, Aurkb, Mki67, cdkn1a/p21, Pmaip1/Noxa), normalized to Gapdh (n = 4). For (C–G), *P < 0.05, **P < 0.01, ***P < 0.001 versus Het; #P < 0.05, ###P < 0.001 versus saline.